Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5461338 | 0.87 | CA12 (0.40) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL28570198 | 0.86 | KCNH2 (0.40) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL8683462 | 0.81 | CA12 (0.39) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL5452741 | 0.81 | CA12 (0.36) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL4700076 | 0.75 | CA12 (0.37) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL15009297 | 0.75 | CA12 (0.52) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL14428389 | 0.73 | SIGMAR1 (0.36) | CA12CA1CA2CA9 | |
| SCHEMBL6365684 | 0.72 | ATM (0.37) | CA12CA1CA2CA9MEN1 | |
| Diethylamine SCHEMBL6365058 | 0.72 | CA12 (0.52) | CA12CA1CA2CA9 | |
| SCHEMBL15008318 | 0.71 | MEN1 (0.36) | CA12CA1CA2CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2007-08-16 | — | — | US | claimed |
| EP-0972517-B1 | Use of 1,2,4-benzotriazine oxides for the preparation of a medicament for the treatment of tumors | UNIV LELAND STANFORD JUNIOR (US) | 2004-07-07 | — | — | EP | claimed |
| US-6362184-B1 | KILLING TUMOR CELLS | SRI INTERNATIONAL | 2002-03-26 | — | — | US | claimed |
| EP-0649658-B1 | Use of 1,2,4-benzotriazine oxides for the manufacture of a medicament for the treatment of tumors | UNIV LELAND STANFORD JUNIOR (US) | 2000-06-14 | — | — | EP | claimed |
| EP-0972517-A2 | Use of 1,2,4-benzotriazine oxides for the preparation of a medicament for the treatment of tumours | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-01-19 | — | — | EP | claimed |
| EP-0413706-B1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | STANFORD RES INST INT (US) | 1998-09-02 | — | — | EP | claimed |
| EP-0649658-A1 | Method of tumor treatment | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1995-04-26 | — | — | EP | claimed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| US-5484612-A | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1996-01-16 | — | — | US | disclosed |
| EP-0649658-A1 | Method of tumor treatment | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1995-04-26 | — | — | EP | disclosed |
| US-5175287-A | Lower alkyl nitrite under reductive deamination | S R I INTERNATIONAL (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0478545-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1992-04-08 | — | — | EP | disclosed |
| WO-1991004028-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1991-04-04 | — | — | WO | disclosed |
| EP-0413706-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1991-02-27 | — | — | EP | disclosed |
| WO-1989008647-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1989-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | CA12 1360/4885CA1 1837/4885CA2 3064/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | CA12 1360/4885CA1 1837/4885CA2 3064/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | CA12 1360/4885CA1 1837/4885CA2 3064/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | CA12 1133/4885CA1 725/4885CA2 2980/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | CA12 4392/4885CA1 3124/4885CA2 4402/4885 |
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | HIF1AN, HIF1A, HYOU1 | CA12 1186/4885CA1 661/4885CA2 21/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | CA12 1360/4885CA1 1837/4885CA2 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.